You can be on Entrepreneur’s cover!

Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors iBio remains a dark horse in the ongoing development of Covid-19 vaccines. But an intriguing new candidate and a resolution of intellectual property issues makes a long, albeit small position in IBIO stock justified for risk-tolerant investors.

By Chris Markoch

entrepreneur daily

This story originally appeared on MarketBeat

Depositphotos.com contributor/Depositphotos.com via MarketBeat

iBio (NYSEAMERICAN:IBIO) was one of the more fascinating stocks at the onset of the Covid-19 pandemic. The company already possessed a proprietary system for producing proteins from plants. And in the early days of the pandemic, iBio introduced a vaccine candidate, IBIO-201, with hopes that it could receive funding from Operation Warp Speed (OWS)

That news pushed IBIO stock from about 30 cents a share to over $6 a share. However the company wasn't selected for OWS. And it found itself engaged in a lawsuit with Fraunhofer USA which threatened the intellectual property surrounding its proprietary FastPharming technology.

The stock dropped sharply but has found support that's keeping it above the psychologically important $1 threshold. One reason for that is that the company is taking another whack at a next-generation Covid-19 vaccine. And, in the last month, the company has managed to put is

I don't often find myself pondering taking a position in a penny stock. Most penny stocks are inexpensive for a reason. Nevertheless, I find myself intrigued by iBio now that the company has put its legal troubles behind it.

An Innovative Approach to Vaccine Development

For investors unfamiliar with iBio, I threw a lot at you in that introduction. So let me quickly take a step back. IBio uses plant-based technology to enable next-gen biologics. The company's proprietary FastPharming system produces proteins from plants. Because they're plant-based, these proteins can be rapidly developed in the production of vaccines and antibody treatments.

In addition to the speed, the premise behind the FastPharming technology is that plants are a more sustainable source for producing biologics.

Vaccine 2.0

IBio's initial vaccine candidate, IBIO-201, combined antigens from the novel coronavirus spike protein and fused the with the company's patented LicKM booster molecule in an effort to boost immune response. Using the LicKM molecule was an attempt to achieve single-dose immunity.

Although the United States is amply supplied with vaccines, iBio continues to move IBIO-201 through the clinical trial phase. Early in May 2021, the company reported successful toxicology study results for IBIO-201.

However, anticipating the potential of variants that may lessen or negate entirely the effect of the existing Covid-19 vaccines, iBio set out to design a second Covid-19 vaccine. This one, IBIO-202 focuses on the nucleocapsid (N protein).

But to get this vaccine to market will take time and funding. The company may be eligible for funding from the Coalition for Epidemic Preparedness Innovations (CEPI). If it could get funding, that would be a significant catalyst for the stock.

A Risk of Further Share Dilution

For a biotech, the process of bringing a drug to market takes a long time and a lot of money. On the company's earnings call, management reported $103.9 million in cash, cash equivalents and debt instruments as of the end of March 2021.

However, even with the nearly $12 million in aggregate cash recovery the company will receive as part of the resolution of its lawsuit with Fraunhofer USA, iBio is only funded until the end of March 2023. This prompted a question from an analyst about whether the company would have to issue another share offering to raise money.

As you would expect, the company was non-committal and expressed hope that it would be able to generate non-dilutive revenue from its FastPharming system or through funding it will receive to proceed with its Covid-19 vaccine candidate.

What to Do With IBIO Stock?

Although inexpensive stocks typically attract trading activity, I don't see a good setup for IBIO stock right now. However, as a component of the speculative part of your portfolio, a long, albeit small position in iBio is worthy of consideration. It's certainly more compelling with the stock trading near $1.50 than almost $6 as it was last summer.

Of the two revenue opportunities in front of iBio, I see the potential for government funding to be more likely than that it finds a substantive partnership for its FastPharming technology. But clearly getting funding through either outlet would be a huge catalyst for IBIO stock.

Featured Article: What is Call Option Volume?

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Growing a Business

To Achieve Sustainable Success, You Need to Stop Focusing on Disruption. Here's Why — and What You Must Focus on Instead.

Instead of zeroing in solely on disruptive innovation, embrace a pragmatic approach to innovation, recognizing and leveraging the potential within ongoing industry shifts.

Business News

Mark Zuckerberg Says This CEO Is the 'Taylor Swift' of Tech

Meta's CEO posed with Nvidia CEO Jensen Huang on Instagram Wednesday.

Real Estate

3 Emerging Trends Shaping the Future of Real Estate

These three innovations are reshaping the real estate industry — discover tips for effectively covering these trends.

Leadership

What We Have to Gain By Talking About Grief and Loss At Work

I lost my husband to cancer during Covid — here's how it changed how I lead at work.

Side Hustle

This Mom Started a Side Hustle After a 'Shocking' Realization in the Toy Aisle. Her Product Was in Macy's Within the Year — Seeing Nearly $350,000 in Sales.

Elenor Mak, now founder of Jilly Bing, didn't plan to start a business — but the search for a doll that looked like her daughter inspired her to do just that.

Fundraising

Avoid These 9 Pitch Deck Mistakes When Asking Others For Money

Crafting an efficient pitch deck requires serious effort, but at least it's not wandering in the dark since certain rules are shaped by decades of relationships between startups and investors.